Palvella Therapeutics, Inc.
PVLA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583648
In the last 90 days, Palvella Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 196 institutions reported holding it in 13F filings for Q2 2026, worth $2.15B in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Palvella Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 140
- +41 vs. Q3 2025
- Shares held
- 9.76M
- +1.23M (+14.5%) vs. Q3 2025
- Total value
- $1.02B
- +$487.1M (+91.1%) vs. Q3 2025
- New holders
- 53
- 42 more added
- Sold out
- 12
- 29 more reduced
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PVLA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 196 | $2.15B |
| Q1 2026 | 180 | $1.64B |
| Q4 2025 | 140 | $1.02B |
| Q3 2025 | 100 | $534.5M |
| Q2 2025 | 67 | $133.2M |
| Q1 2025 | 41 | $143.4M |
| Q4 2024 | 33 | $48.4M |
| Q3 2024 | 25 | $10.1M |
| Q2 2024 | 20 | $3.57M |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Palvella Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Superstring Capital Management LP | 25,469 | $2.67M | 1.43% | +25,469 | New |
| Royce & Associates LP | 30,010 | $3.14M | 0.03% | −19,499−39.4% | Reduced |
| Bank of America Corp | 30,272 | $3.17M | 0.00% | +25,583+545.6% | Added |
| UBS Group AG | 36,505 | $3.82M | 0.00% | +16,066+78.6% | Added |
| Blue Owl Capital Holdings LP | 40,259 | $4.21M | 1.30% | −55,000−57.7% | Reduced |
| Lisanti Capital Growth, LLC | 41,470 | $4.34M | 1.03% | +41,470 | New |
| Neuberger Berman Group LLC | 44,901 | $4.70M | 0.00% | +44,901 | New |
| UBS Asset Management Americas Inc | 47,681 | $4.99M | 0.00% | +47,681 | New |
| Invesco Ltd. | 54,273 | $5.68M | 0.00% | +5,663+11.6% | Added |
| Northern Trust Corp | 54,490 | $5.70M | 0.00% | +487+0.9% | Added |
| Artia Global Partners LP | 59,200 | $6.20M | 1.00% | +59,200 | New |
| Clearbridge Investments, LLC | 60,628 | $6.35M | 0.01% | +60,628 | New |
| AWM Investment Company, Inc. | 69,416 | $7.27M | 0.70% | 00.0% | Unchanged |
| Siren, L.L.C. | 75,000 | $7.85M | 0.23% | +75,000 | New |
| Point72 Asset Management, L.P. | 77,297 | $8.09M | 0.01% | −240,012−75.6% | Reduced |
| NEXTBio Capital Management LP | 82,686 | $8.65M | 5.08% | +82,686 | New |
| Clio Asset Management LLC | 91,642 | $9.59M | 7.45% | +10.0% | Added |
| Goldman Sachs Group Inc | 98,935 | $10.4M | 0.00% | −137,695−58.2% | Reduced |
| Eventide Asset Management, LLC | 101,748 | $10.6M | 0.17% | +101,748 | New |
| Samsara BioCapital, LLC | 104,817 | $11.0M | 1.13% | −104,817−50.0% | Reduced |
| Balyasny Asset Management LLC | 108,880 | $11.4M | 0.02% | −57,655−34.6% | Reduced |
| Fred Alger Management, LLC | 150,026 | $15.7M | 0.06% | −36,725−19.7% | Reduced |
| Geode Capital Management, LLC | 178,992 | $18.7M | 0.00% | +10,882+6.5% | Added |
| MPM Oncology Impact Management LP | 205,745 | $21.5M | 2.46% | +138,322+205.2% | Added |
| Artisan Partners Limited Partnership | 211,553 | $22.1M | 0.03% | +211,553 | New |
| Morgan Stanley | 220,662 | $23.1M | 0.00% | +82,157+59.3% | Added |
| FMR LLC | 231,760 | $24.3M | 0.00% | +121,314+109.8% | Added |
| Perceptive Advisors LLC | 266,287 | $27.9M | 0.51% | −128,806−32.6% | Reduced |
| Alliancebernstein L.P. | 269,027 | $28.2M | 0.01% | +269,027 | New |
| Woodline Partners LP | 300,536 | $31.5M | 0.12% | −45,213−13.1% | Reduced |
| Federated Hermes, Inc. | 368,038 | $38.5M | 0.06% | +28,991+8.6% | Added |
| Jennison Associates LLC | 387,483 | $40.6M | 0.02% | +280,573+262.4% | Added |
| Summit Partners Public Asset Management, LLC | 389,420 | $40.8M | 1.15% | +354,525+1,016.0% | Added |
| State Street Corp | 420,462 | $44.0M | 0.00% | +283,211+206.3% | Added |
| BlackRock, Inc. | 559,065 | $58.5M | 0.00% | +71,449+14.7% | Added |
| Vanguard Group Inc | 560,616 | $58.7M | 0.00% | +65,960+13.3% | Added |
| First Light Asset Management, LLC | 709,141 | $74.2M | 5.67% | +167,597+30.9% | Added |
| Frazier Life Sciences Management, L.P. | 722,400 | $75.6M | 2.03% | 00.0% | Unchanged |
| BVF Inc | 879,009 | $92.0M | 3.10% | −282,240−24.3% | Reduced |
| Suvretta Capital Management, LLC | 892,400 | $93.4M | 2.33% | +70,000+8.5% | Added |
| Nantahala Capital Management, LLC | 0 | $0 | 0.00% | −250,062−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −64,746−100.0% | Sold out |
| Standard Life Aberdeen plc | 0 | $0 | 0.00% | −51,243−100.0% | Sold out |
| Sectoral Asset Management Inc | 0 | $0 | 0.00% | −49,115−100.0% | Sold out |
| J. Goldman & Co LP | 0 | $0 | 0.00% | −40,692−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −25,532−100.0% | Sold out |
| Eversept Partners, LP | 0 | $0 | 0.00% | −11,343−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −10,017−100.0% | Sold out |
| Apis Capital Advisors, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −8,008−100.0% | Sold out |
| Toronto Dominion Bank | 0 | $0 | 0.00% | −2,500−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −91−100.0% | Sold out |
| Point72 Europe (London) LLP | – | – | – | – | Not filed |